Skip to content
Global sound
Post-Hoc Live

Post-Hoc Live

by Endpoints News

Latest episode
The US midterm elections and biopharma

About this podcast

Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations.

Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: [email protected]

Episodes

The newest 20 of 55 episodes

  • The US midterm elections and biopharma · 43 min · Episode 54The results of the midterm elections could swing control of Congress — with a range of potential impacts for biopharma, from the US posture towards China to drug pricing. After…
  • Is biotech’s future full of zero-employee startups? · 39 min · Episode 53Anthropic announced this week that it had acquired Mithril Medicine, a one-person biotech. It’s an early test of the idea that, with heavy use of AI and contracts with external…
  • Did Treasury’s COINS rule just end China biotech deals? · 42 min · Episode 52For weeks, biotech and pharma have been waiting for the Treasury Department’s proposed rule on the COINS Act and how it would affect the industry. Thursday’s announcement was a…
  • Live from DC: Will Congress put a stop to China biotech deals? · 24 min · Episode 51There isn't a lawmaker on Capitol Hill who's publicly taken a more conservative stance to biopharma's deal spree in China than Rep. John Moolenaar (R-MI), chairman of the House…
  • Live from DC: Is secrecy the solution? · 27 min · Episode 50What do you do when you announce a drug program, then turn around and find out that there are a dozen competitors in China working on the same idea? For many US biotechs, the…
  • Live from DC: What do we really mean when we talk about biosecurity risk and China? · 26 min · Episode 49Huge genetic databases. Drug ingredient supply chains. A next pandemic. War with Taiwan. Economic competition. A huge number of topics and scenarios get lumped into the "China…
  • Live from DC: Can the FDA steer clinical trials back to the US? · 23 min · Episode 48If investment restrictions are the potential consequences to a drug industry that's looked overseas for new assets and early trials, then what's the incentive to come back? The…
  • Live from Boston: How pharma thinks about China · 24 min · Episode 47As large pharma companies increasingly turn to China to fill their pipelines, what long-term affect will it have on their strategy and operations? Pfizer's Andrew Baum shares the…
  • Live from Boston: Investor math versus industrial priority · 45 min · Episode 46Should investors embrace China’s fast-moving, fast-growing biotech sector, or should there be barriers to protect and preserve an industry that the US has dominated for decades?…
  • Live from Boston: Has China changed how we build companies? · 27 min · Episode 45In a world where promising drugs are quickly copied, improved on and raced into trials, is science still a differentiator? Strand Therapeutics CEO Jake Becraft and Roivant…
  • The case for — and against — an AZ-BMS megadeal · 35 min · Episode 44AstraZeneca and Bristol Myers Squibb are reportedly in talks to combine, which would be one of the largest mergers the biopharma industry has ever seen. What could each company…
  • Record IPOs — with Parabilis and Kailera’s CEOs · 34 min · Episode 43Kailera broke records with its $625 million IPO in April. But its high-water mark didn’t last long — in June, Parabalis made a $670 million debut, putting its own name on top of…
  • Are the China hawks winning? · 42 min · Episode 42WuXi is back on the Pentagon’s blacklist. The United States Treasury might restrict investments in Chinese biotech. Despite wave after wave of big pharma announcements around…
  • How much is everyone in biopharma getting paid? · 33 min · Episode 41CEO pay keeps going up, and up, and up. What do the pay ratios at pharmas say about the state of the industry as a whole, and how do the eye-popping numbers affect global…
  • How to stabilize US biotech — with Dr. Jeremy Levin · 33 min · Episode 40Jeremy Levin has seen the biopharma industry from practically every vantage point. Now, with decades of experience under his belt, he’s out front in the chorus of veterans…
  • Makary's out: Live from the FT Summit · 29 min · Episode 39Marty Makary resigned as FDA commissioner on Tuesday after a turbulent tenure at the head of the agency. The Endpoints and Financial Times teams sat down at the US Pharma and…
  • Q1 earnings recap with Endpoints News · 38 min · Episode 38Thanks to our premium subscribers who joined us live for this special episode of Post-Hoc Live. Catch up on the recording now:Are more deals coming, after a deal-heavy Q1? How…
  • Trust, MAHA, and what’s next for the CDC · 34 min · Episode 37The CDC hasn’t had a Senate-confirmed director since August. But last week, President Trump announced his next pick — Erica Schwartz, a former deputy surgeon general. She’s a…
  • The spring deals bonanza · 37 min · Episode 36Pharma companies went on a dealmaking spree over the past few weeks, signing acquisitions worth up to $25.5B in two weeks in March alone. It’s shaping up to be a big year — if…
  • The politics of vaccines — with former congressman Dr. Michael Burgess · 35 min · Episode 35With the midterms looming, Trump’s HHS seems to be backing off vaccines and pivoting toward healthy eating — playing up the aspects of RFK Jr.’s agenda that are popular, rather…

More like this

All News podcasts →

Live, last hour: 15,323 songs on 7,564 stations in 142 countries

Discover the world through radio

More ways to discover (9)

Heard something good? Save it, or open it straight away in Spotify.

Radio 538 luisteren - Live!Popular right now